Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C et al (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro-oncology. 19:v1–v88
Article
Google Scholar
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
Article
CAS
Google Scholar
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820
Article
Google Scholar
Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR et al (2013) The somatic genomic landscape of glioblastoma. Cell. 155:462–477
Article
CAS
Google Scholar
Quan AL, Barnett GH, Lee S-Y, Vogelbaum MA, Toms SA, Staugaitis SM et al (2005) Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 63:695–703
Article
CAS
Google Scholar
Lassman AB, Aldape KD, Ansell PJ, Bain E, Curran WJ, Eoli M et al (2019) Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. J Neuro-Oncol 144:205–210
Article
Google Scholar
French PJ, Eoli M, Sepulveda JM, de Heer I, Kros JM, Walenkamp A, et al (2019) Defining EGFR amplification status for clinical trial inclusion. Neuro-oncology 21(10):1263-1272.
An Z, Aksoy O, Zheng T, Fan Q-W, Weiss WA (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene. 37:1561–1575
Article
CAS
Google Scholar
Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H et al (2017) ACT IV trial investigators. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18:1373–1385
Article
CAS
Google Scholar
Uhm JH, Ballman KV, Wu W, Giannini C, Krauss JC, Buckner JC et al (2011) Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo/north central Cancer treatment group study N0074. Int J Radiat Oncol Biol Phys 80:347–353
Article
CAS
Google Scholar
Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF et al (2014) Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: north American brain tumor consortium trial 04-02. Neuro-oncology. 16:567–578
Article
CAS
Google Scholar
Sepúlveda-Sánchez JM, Vaz MÁ, Balañá C, Gil-Gil M, Reynés G, Gallego Ó et al (2017) Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. Neuro-oncology. 19:1522–1531
Article
Google Scholar
van den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel J-S, et al (2019) INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFRamplified glioblastoma. Neuro-oncology. In press.
Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB et al (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol 136:805–810
Article
CAS
Google Scholar
Stichel D, Ebrahimi A, Reuss D, Schrimpf D, Ono T, Shirahata M et al (2018) Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol 136:793–803
Article
Google Scholar
Cassinari K, Quenez O, Joly-Hélas G, Beaussire L, Le Meur N, Castelain M et al (2019) A simple, universal, and cost-efficient digital PCR method for the targeted analysis of copy number variations. Clin Chem 65:1153–1160
Article
CAS
Google Scholar
Boeva V, Popova T, Lienard M, Toffoli S, Kamal M, Le Tourneau C et al (2014) Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data. Bioinformatics. 30:3443–3450
Article
CAS
Google Scholar
Bobée V, Ruminy P, Marchand V, Viailly P-J, Abdel Sater A, Veresezan L et al (2017) Determination of molecular subtypes of diffuse large B-cell lymphoma using a reverse transcriptase multiplex ligation-dependent probe amplification classifier: a CALYM study. J Mol Diagn. 19:892–904
Article
Google Scholar
Piton N, Ruminy P, Gravet C, Marchand V, Colasse É, Lamy A et al (2018) Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma. Lab Investig 98:371–379
Article
CAS
Google Scholar
Drieux F, Ruminy P, Abdel-Sater A, Lemonnier F, Viailly P-J, Fataccioli V, et al (2019) Defining the signatures of peripheral T-cell lymphoma, with a targeted 20-markers gene expression profiling assay (RT-MLPA). Haematologica. In press.
Chiu A, Ayub M, Dive C, Brady G, Miller CJ (2017) Twoddpcr: an R/bioconductor package and shiny app for droplet digital PCR analysis. Bioinformatics. 33:2743–2745
Article
CAS
Google Scholar
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722
Article
CAS
Google Scholar
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708
Article
CAS
Google Scholar
Ramkissoon SH, Bi WL, Schumacher SE, Ramkissoon LA, Haidar S, Knoff D et al (2015) Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro-oncology. 17:1344–1355
Article
CAS
Google Scholar
McNulty SN, Cottrell CE, Vigh-Conrad KA, Carter JH, Heusel JW, Ansstas G et al (2019) Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling. Hum Pathol 86:170–181
Article
CAS
Google Scholar
Sharifi Z, Abdulkarim B, Meehan B, Rak J, Daniel P, Schmitt J et al (2019) Mechanisms and antitumor activity of a binary EGFR/DNA-targeting strategy overcomes resistance of Glioblastoma stem cells to Temozolomide. Clin Cancer Res 25:7594–7608
Article
Google Scholar
Koga T, Li B, Figueroa JM, Ren B, Chen CC, Carter BS et al (2018) Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development. Neuro-oncology. 20:1310–1320
Article
CAS
Google Scholar
Saxena D, Sheikh S, Kao G, Binder ZA, Alonso-Basanta M, O’Rourke DM et al (2019) Rapid and ultrasensitive digital PCR (dPCR) profiling of EGFRvIII in tumor cells and tissues. Neurooncol Adv 1:vdz030
PubMed
PubMed Central
Google Scholar
Zacher A, Kaulich K, Stepanow S, Wolter M, Köhrer K, Felsberg J et al (2017) Molecular diagnostics of Gliomas using next generation sequencing of a Glioma-tailored gene panel. Brain Pathol 27:146–159
Article
CAS
Google Scholar
Miller ML, Tome-Garcia J, Waluszko A, Sidorenko T, Kumar C, Ye F et al (2019) Practical Bioinformatic DNA-sequencing pipeline for detecting oncogene amplification and EGFRvIII mutational status in clinical Glioblastoma samples. J Mol Diagn. 21:514–524
Article
CAS
Google Scholar
Kuśmirek W, Szmurło A, Wiewiórka M, Nowak R, Gambin T (2019) Comparison of kNN and k-means optimization methods of reference set selection for improved CNV callers performance. BMC Bioinformatics [cited 2020 Feb 26];20. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537193/
Grasso C, Butler T, Rhodes K, Quist M, Neff TL, Moore S et al (2015) Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data. J Mol Diagn 17:53–63
Article
CAS
Google Scholar